期刊文献+

络衡方对高血脂大鼠血液流变学的实验研究 被引量:13

Hemorhedogical Study of Luoheng Prescription for Hyperlipidemic Rats
暂未订购
导出
摘要 目的观察络衡方对高血脂症实验大鼠血液流变学的影响。方法喂饲高脂饲料及灌喂高脂溶液建立高血脂大鼠模型,检测生化指标。结果络衡方可显著降低高脂模型,大鼠的谷丙转氨酶、碱性磷酸酶、低密度脂蛋白、总胆固醇水平;血液流变学检测发现络衡方能显著降低全血黏度和红细胞压积。结论改善体内的脂肪代谢可能是络衡方治疗急性冠状动脉综合征的机理之一。 Objective To observe the effect of Luoheng prescription on hemorheology of rats. Methods By feeding rats with highfat diet and solution, a rat model of hyperlipidemia was established. Results Observation of bi ochemical parameters showed that Luoheng prescription could significantly reduce alanine aminotransferase, alkaline phosphatase, lowdensity lipoprotein, total cholesterol of fat rats. Hemorheological values showed Luoheng prescrip tion significantly reduced the whole blood viscosity and hematocrit. Conclusion Improving the body's fat metabolism may be one of the mechanisms of Luoheng prescription for acute coronary syndrome.
出处 《解放军药学学报》 CAS 2012年第6期495-498,共4页 Pharmaceutical Journal of Chinese People's Liberation Army
基金 国家青年科学基金项目 No.30901955
关键词 络衡方 高血脂 血液流变学 急性冠状动脉综合征 Luoheng prescription high-fat hemorheology acute coronary syndrome
  • 相关文献

参考文献7

  • 1Friedewald WF.Estimation of concentration of low density lipoprotein cholesterol without use of preparative ultra centrifugation[J].Clin Chem,1972,18:499-502.
  • 2王显 杨巨成.急性冠脉综合征“络风内动”假说及实践.中华中医药杂志,2002,17(9):19-22.
  • 3Riina O,Petri TK,Mikko IM,et al.Complement regulation in human atherosclerotic coronary lesions Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway,and that C5b-9 is formed via the alternative complement pathway[J].Atherosclerosis,2007,192(1):40-48.
  • 4钱卫东,庄德成,朱学云,钱小奇.高脂血症中医病因病机探讨[J].湖北中医杂志,2001,23(11):5-6. 被引量:26
  • 5胡振波,姜贺,徐京育.复方丹参饮治疗慢性稳定型心绞痛伴高脂血症的临床观察[J].中医药学报,2009,37(1):31-32. 被引量:21
  • 6Lustep HL,Clark WM.Current status of neuroprotective agents in the treatment of acute ischemic stroke[J].Curr Neurol Neurosci Rep,2000,1 (1):13-18.
  • 7Granger CB,Mahaffey KW,Weaver WD,et al.Pexelizumab,an anti-C5 complement antibody,as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction:the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial[J].Circulation,2003,108(5):1184-1190.

二级参考文献1

共引文献49

同被引文献305

引证文献13

二级引证文献277

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部